KAPA

KAIROS PHARMA LTD

KAPA·48301N104·US·Common Stock·Healthcare - Biotechnology-13D/G

KAPA (KAIROS PHARMA LTD) is held by 12 institutional investors as of Q2 2026. Largest holders: CITADEL ADVISORS LLC ($118,883), VANGUARD CAPITAL MANAGEMENT LLC ($89,041), GEODE CAPITAL MANAGEMENT, LLC ($30,282). Net institutional sentiment: Mixed.

12
Holders
(1 Elite)
$321,601
Total Value
64% (11)
Consensus
7 buying - 4 selling
13F: Insider & Congress: Updated regularly
KAPA

Smart Money Verdict

View all
Loading verdict
Held by 12 funds
1 elite

Who's Trading

Source dates: Price Aug 27, 2026 · Insiders none · Activists Aug 14, 2025 · Congress none

ActivistARArmistice Capital, LLC5.0%Aug 14, 2025

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
New
309,834$118,8830.0%-32.29%
34
Unchanged
231,878$89,0410.0%-58.06%
0
Decreased
78,924(-29.1%)$30,2820.0%-70.40%
0
Unchanged
63,884$24,5310.0%-58.06%
0
Unchanged
44,286$16,9930.0%-71.74%
0
New
33,749$12,9490.0%-32.29%
27
New
29,292$11,2390.0%-32.29%
27
Unchanged
24,100$9,2470.0%-76.79%
0
New
14,918$5,7240.0%-32.29%
21
New
6,261$2,4040.0%-32.29%
19
New
723$2770.0%-32.29%
17
New
82,092$310.0%-32.29%
15
Exited
0(-100.0%)$60.0%-38.06%
0
Exited
0(-100.0%)$12,0000.0%-45.07%
0
Exited
0(-100.0%)$22,1050.0%-57.55%
0
KAPAKAPAKAIROS PHARMA LTD

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used